Ignite Creation Date:
2025-12-24 @ 1:06 PM
Ignite Modification Date:
2026-01-28 @ 5:17 PM
Study NCT ID:
NCT02625961
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2015-12-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-10
Start Date Type:
ACTUAL
Primary Completion Date:
2025-11-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-11-05
Completion Date Type:
ACTUAL
First Submit Date:
2015-12-07
First Submit QC Date:
None
Study First Post Date:
2015-12-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-20
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED